NASDAQ:MTVA MetaVia Q3 2026 Earnings Date & Estimates $1.41 +0.02 (+1.44%) As of 12:04 PM Eastern This is a fair market value price provided by Massive. Learn more. MetaVia is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 5, 2026TimeBefore Market OpensConference Call DateNovember 6, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from MetaVia in Q3 2026MetaVia is expected to post earnings of -$0.7333 per share. In the same quarter a year earlier MetaVia reported -$1.54 per share. MetaVia last reported on August 6, 2026, posting -$0.90 per share and missing the -$0.82 consensus estimate. MetaVia has beaten the consensus EPS estimate in 3 of its last 5 quarters.Consensus EstimatesConsensus EPS-$0.7333Prior-Year EPS-$1.54Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.90 (Missed by -$0.08)EPS Beat Rate3 of last 5 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ3 2025 Earnings Report MetaVia Q3 2026 Earnings FAQ When does MetaVia report Q3 2026 earnings? MetaVia (NASDAQ:MTVA) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is MetaVia's Q3 2026 earnings call? MetaVia's Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for MetaVia? Analysts expect MetaVia to post earnings of -$0.7333 per share for Q3 2026. MetaVia Earnings HeadlinesMetaVia Appoints Sarah Browne As CMOOctober 13, 2026 | rttnews.comMetavia Inc. Announces Appointment of Sarah Browne, M.D. as Chief Medical Officer, Effective October 12, 2026October 13, 2026 | marketscreener.comMMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.October 23 at 1:00 AM | The Oxford Club (Ad)MetaVia Appoints Seasoned Clinical Development Executive Sarah Browne, M.D., as Chief Medical OfficerOctober 13, 2026 | prnewswire.comMTVA: Preclinical Findings Support DA-1726 Waist Circumference ReductionSeptember 10, 2026 | finance.yahoo.comMetaVia Inc.: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference ReductionSeptember 9, 2026 | finanznachrichten.deSee More MetaVia Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like MetaVia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MetaVia and other key companies, straight to your email. Email Address About MetaViaMetaVia (NASDAQ:MTVA), Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s programs are designed to address conditions including excess weight, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), a form of fatty liver disease associated with metabolic dysfunction. MetaVia’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed as a potential treatment for obesity and related metabolic complications. The company is also developing DA-1241, an oral investigational GPR119 agonist intended for the treatment of MASH and type 2 diabetes. These candidates are in clinical development and have not been approved for commercial use. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and adopted the MetaVia name as part of its strategic focus on metabolic disease. MetaVia’s development programs are based in part on technology licensed from Dong-A Socio Holdings and its affiliates. The company is headquartered in the United States and conducts clinical development activities in collaboration with international partners.View MetaVia ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir's Next Big Test Isn't a Partnership—It's the NumbersKinder Morgan's $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings BeatCapital One Earnings: After a Double Beat the Rally Is OnTractor Supply's Q3 Beat Plants the Seeds for a Stock ReboundWD-40 Could Reward Patient Investors—Here's WhyTexas Paused Data Center Hookups—2 Power Stocks Are Waiting on the VerdictIs Texas Instruments Setting Up for Its Next Big Breakout? Upcoming Earnings Verizon Communications (10/26/2026)Nucor (10/26/2026)Public Storage (10/26/2026)Welltower (10/26/2026)Cadence Design Systems (10/26/2026)Hilton Worldwide (10/27/2026)Royal Caribbean Cruises (10/27/2026)CocaCola (10/27/2026)Coca Cola Femsa (10/27/2026)Baker Hughes (10/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
